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Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease, which affects the structure of heart muscle tissue. The clinical
symptoms include arrhythmias, progressive heart failure, and even sudden cardiac death but themutation carrier can also be totally
asymptomatic. To date, over 1400mutations have been linked to HCM,mostly in genes encoding for sarcomeric proteins. However,
the pathophysiological mechanisms of the disease are still largely unknown. Two founder mutations for HCM in Finland are
located inmyosin-binding protein C (MYBPC3-Gln1061X) and𝛼-tropomyosin (TPM1-Asp175Asn) genes.We studied the properties
of HCM cardiomyocytes (CMs) derived from patient-specific human induced pluripotent stem cells (hiPSCs) carrying either
MYBPC3-Gln1061X or TPM1-Asp175Asnmutation. Both types of HCM-CMs displayed pathological phenotype of HCM but, more
importantly, we found differences between CMs carrying either MYBPC3-Gln1061X or TPM1-Asp175Asn gene mutation in their
cellular size, Ca2+ handling, and electrophysiological properties, as well as their gene expression profiles. These findings suggest
that even though the clinical phenotypes of the patients carrying either MYBPC3-Gln1061X or TPM1-Asp175Asn gene mutation
are similar, the genetic background as well as the functional properties on the cellular level might be different, indicating that the
pathophysiological mechanisms behind the two mutations would be divergent as well.
1. Introduction
Hypertrophic cardiomyopathy (HCM) is one of the most
common genetic cardiac diseases with worldwide prevalence
of 1 : 500, as well as the most common cause of sudden
cardiac death (SCD) among young competing athletes. HCM
is inherited in an autosomal dominant pattern. Nevertheless,
a large clinical diversity and age-related penetrance are typical
for HCM. On the tissue level, HCM is characterized by the
disarray of cardiomyocytes (CMs) and fibrosis of cardiac
tissue, as well as thickened interventricular septum or free
left ventricular wall. Clinical symptoms include arrhythmias,
progressive heart failure, and even SCD, but on the other
hand the mutation carrier can be completely asymptomatic.
Altogether more than 1400 mutations in 11 genes encoding
for the sarcomeric proteins have been identified and related
to HCM. The majority of the mutations are found either in
the 𝛽-myosin heavy chain (MYH7) or in the myosin-binding
protein C (MYBPC3) genes [1]. In Finland, two founder
mutations located in MYBPC3 and 𝛼-tropomyosin (TPM1)
genes and one common mutation in MYH7 gene together
account around 24% of all Finnish HCM cases [2, 3].
Although the genetic information related to HCM has
been growing in the recent years due to the development
of sequencing technologies, exact information of the disease
mechanisms remains unclear.Thus, currentmedication of the
disease is directed toward the symptom relief and there is no
specific therapy to prevent the onset or progression of the
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disease [1]. Most of the HCM studies have been conducted
with model systems, mainly either with transgenic mice or
by studying human tissues obtained from surgical myectomy
from end-stage HCM patients [4]. However, animal models
carry only the mutated gene lacking the rest of the genome
and myectomy samples are obtained from patients in the late
stage of HCM development. Therefore, the discovery of the
human induced pluripotent stem cells (hiPSCs) has offered a
new valuable tool to model HCM and other cardiac diseases
and to study the underlying disease mechanisms [5]. To date,
hiPSCs have already been used to model a variety of cardiac
diseases: electrical defects, for example, long-QT syndrome
[6–8] and catecholaminergic polymorphic ventricular tachy-
cardia (CPVT) [9, 10] as well as cardiomyopathies including
dilated cardiomyopathy (DCM) [11] and HCM [12–14].
Here we have derived hiPSCs from patients carrying two
of the Finnish HCM founder mutations either in MYBPC3
(MYBPC3-Gln1061X) or in TPM1 (TPM1-Asp175Asn) gene.
We have differentiated the patient-specific hiPSCs into CMs
and compared the phenotypes of the diseased and control
CMs.
2. Materials and Methods
2.1. Ethical Issues. This study was conducted in accordance
with the Ethics Committee of Pirkanmaa Hospital District
to establish, culture, and differentiate hiPSC lines (R08070).
Skin biopsies for hiPSC establishment were received from
the Heart Hospital, Tampere University Hospital, Tam-
pere, Finland. Patients donating skin biopsies signed an
informed consent after receiving both oral and written
descriptions of the study. The teratoma assay, described in
Section 2.3.6, was approved by ELLA-Animal Experiment
Board of Regional State Administrative Agency for Southern
Finland (ESAVI/6543/04.10.03/2011).
2.2. Generation and Culture of Patient-Specific hiPSC Lines.
hiPSC lines were generated from skin’s fibroblasts either with
Sendai reprogramming vectors OCT4, KLF4, c-MYC, and
SOX2 using CytoTune-iPS Reprogramming Kit (Life Tech-
nologies Ltd., Paisley, UK) according to the manufacturer’s
instructions or by using pMX retroviral vectorsOCT4,KLF4,
c-MYC, and SOX2with or without Cre-LoxP site as described
earlier [6, 15]. UTA.13602.HCMT, UTA.02912.HCMT, and
UTA.04511.WT hiPSC lines were generated by using Sendai
vectors and UTA.07801.HCMM and UTA.06108.HCMM
by using pMX retroviral vectors with Cre-LoxP site and
UTA.04602.WT was generated by using pMX retroviral
vectors without Cre-LoxP site. In the present study, one
line of each patient was used. hiPSC lines were derived and
cultured on mouse embryonic fibroblast (MEF) feeder cell
layers (26000 cells/cm2, CellSystems Biotechnologie Vertrieb
GmbH, Troisdorf, Germany) in human pluripotent stem cell
(hPSC) culture medium consisting of knockout-DMEM (ko-
DMEM, Gibco, Life Technologies Ltd.) supplemented with
20% knockout serum replacement (ko-SR, Gibco, Life Tech-
nologies Ltd.), 1% nonessential amino acids (NEAA, Lonza
Group Ltd., Basel, Switzerland), 2mMGlutaMax (Gibco, Life
Technologies Ltd.), 50U/mL penicillin/streptomycin (Lonza
Group Ltd.), 0.1mM 2-mercaptoethanol (Gibco, Life Tech-
nologies Ltd.), and 4 ng/mL basic fibroblast growth factor
(bFGF, PeproTech, Rocky Hill, NJ, USA).
2.3. Characterization of hiPSC Lines
2.3.1. Mutation Analysis by Genotyping. DNA samples from
the hiPSC lines were prepared with TaqMan Sample-to-
SNP Kit (Applied Biosystems, Life Technologies Ltd.) and
the presence of MYBPC3-Gln1061X and TPM1-Asp175Asn
mutation in the patient-specific hiPSC lines was confirmed
by customTaqMan SNPGenotyping Assays (Applied Biosys-
tems, Life Technologies Ltd.) according to the manufacturer’s
instructions. In the genotyping assays, MYBPC3-gene as
well as TPM1-gene was amplified with specific primers.
Furthermore, the presence of themutationswas assessedwith
mutation-specific FAM labeled probes. VIC labeled probes
were used to assess the presence of the wild type allele.
Sequences for the primers and probes used in the assay are
listed in Supplementary Table 1 (see Supplementary Material
available online at http://dx.doi.org/10.1155/2016/1684792).
2.3.2. The Expression of Mutant and Wild Type Alleles in
hiPSC-Derived CMs. RNA samples were collected and
extracted from hiPSC-derived CMs (UTA.04511.WT,
UTA.02912.HCMT, UTA.07801.HCMM, and UTA.06108.
HCMM) with Norgen’s Total RNA Purification Plus Kit
(Norgen Biotek Corp., Ontario, Canada) according to manu-
facturer’s instructions. 50–100 ng of RNA was transcribed to
cDNA by High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Life Technologies Ltd.). The expression
of TPM1-Asp175Asn or MYBPC3-Gln1061X mutation on
mRNA level in the hiPSC-derived CMs was studied by
Custom TaqMan SNP Genotyping Assays (Applied Bio-
systems, Life Technologies Ltd.) similarly as that for
genotyping described above. Sequences for the primers and
probes used in the assay are listed in Supplementary Table 1.
2.3.3. Immunocytochemistry. Undifferentiated hiPSC colo-
nies were fixed with 4% paraformaldehyde (PFA, Sigma-
Aldrich, Saint Louis, USA), stained with primary antibodies
for Nanog (R&D systems Inc., Minneapolis, MN, USA),
OCT4 (R&D systems Inc.), SOX2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), TRA-1-60 (Millipore, Billerica,
MA, USA), and TRA-1-81 (Millipore), and visualized with
secondary antibodies as described before [16]. Finally, the
cells were mounted with Vectashield (Vector Laboratories
Inc., Burlingame, CA, USA) containing 40,6-diamidino-2-
phenylindole (DAPI) for the nuclei staining and imaged with
an Olympus IX51 phase contrast microscope equipped with
fluorescence optics andOlympusDP30BWcamera (Olympus
Corporation, Hamburg, Germany).
2.3.4. RT-PCR. The RNA was extracted from the hiPSC lines
by NucleoSpin RNA II Kit (Macherey-Nagel GmbH & Co.,
Du¨ren, Germany) and 500–1000 ng of RNA was transcribed
to cDNA by High-Capacity cDNA Reverse Transcription Kit
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(Applied Biosystems, Life Technologies Ltd.).The presence of
pluripotency genes Nanog, SOX2, REX1, OCT4, and c-MYC
and the absence of virally imported exogenes (OCT4, SOX2,
c-MYC, and KLF4) were confirmed by RT-PCR. GAPDH
was used as an endogenous control. The primer sequences
for pluripotency genes and virally imported exogenes have
been published earlier [5]. The primer sequences used for
detection of Sendai transgenes are described inCytoTune-iPS
Reprogramming Kit’s manual (Life Technologies Ltd.).
2.3.5. KaryotypeAnalysis. Thekaryotypes of hiPSC lineswere
studied by G-banding (Medix Laboratories, Espoo, Finland)
or by KaryoLite assay [17] (Turku Centre for Biotechnology,
University of Turku, Turku, Finland).
2.3.6. Pluripotency Analysis. The pluripotency of hiPSC lines
was confirmed in vitro by embryoid body (EB) formation
and in vivo by teratoma assay. hiPSCs were removed from
feeder cell layer and cultured in suspension to form EBs. The
EBs were cultured in EB medium consisting of ko-DMEM
supplemented with 20% fetal bovine serum (FBS, Biosera,
Boussens, France), 1% NEAA (Lonza Group Ltd.), 2mM
GlutaMax (Invitrogen, Life Technologies Ltd.), and 50U/mL
penicillin/streptomycin (Lonza Group Ltd) for 4–6 weeks
before RNA extraction. 200 ng of RNA was transcribed to
cDNA for theRT-PCRanalysis.Thepresence of all three germ
layers, endoderm (AFP, SOX17), ectoderm (SOX1, NESTIN,
andMusashi), andmesoderm (KDR, alpha cardiac actin), was
studied with RT-PCR.
For in vivo pluripotency assay, hiPSCs were injected
under the testis capsule of nude mice and the formed
teratomas were collected and fixed with 4% PFA 8 weeks after
the injection. Teratomas were embedded in paraffin, cut in
sections, and stained with haematoxylin and eosin.
2.4. Differentiation of Cardiomyocytes. hiPSCs were dif-
ferentiated into CMs by coculturing with mouse visceral
endodermal-like cells (END-2) (Hubrecht Institute, Utrecht,
Netherlands) as described before [18]. After 15–30 days beat-
ing areas were cut from cocultures and dissociated into single
cells in EB medium by Collagenase A (Roche Diagnostics,
Mannheim, Germany) as described earlier [18] and plated
to 0.1% gelatin-coated cover slips or well plates for further
analysis.
2.5. Characterization of hiPSC-Derived Cardiomyocytes
2.5.1. Immunocytochemistry and Image Analysis. Dissociated
CMs were fixed with 4% PFA and stained with Troponin
T (cTnT, 1 : 2000, ab64623, Abcam, Cambridge, MA, USA),
MYBPC (1 : 400, sc-166081, Santa Cruz Biotechnology), and
TPM1 (1 : 200, sc-73225, Santa Cruz Biotechnology) primary
antibodies, followed by labeling with secondary antibodies.
Images were obtained with Olympus IX51 phase contrast
microscope equipped with fluorescence optics and Olympus
DP308Wcamera (OlympusCorporation) or with Zeiss Axio-
Scope A1 fluorescent microscope and Zeiss AxioCam MRc5
camera (Carl Zeiss, Jena, Germany). Size of the Troponin T
stained CMswas analyzed from 46 to 50 CMs in each cell line
by in-housemade software (unpublishedmethod). CMswere
analyzed from pictures obtained with Olympus IX51 phase
contrast microscope. The proportion of multinucleated CMs
was determined from the same images (46–50 CMs/cell line).
2.5.2. Ca2+ Imaging. The clusters of CMs were cut, dissoci-
ated, plated on 0.1% gelatin-coated coverslips, and cultured
for 1, 3, and 6 weeks. To study the Ca2+ handling properties of
hiPSC-derived CMs, cells were loaded with 4 𝜇MFura-2 AM
(Molecular Probes, Life Technologies Ltd.) for 30 minutes
in perfusate medium. The perfusate medium consisted of
(in mM) 137 NaCl, 5 KCl, 0.44 KH
2
PO
4
, 20 HEPES, 4.2
NaHCO
3
, 5 D-glucose, 2 CaCl
2
, 1.2MgCl
2
, and 1Na-pyruvate
dissolved in H
2
O. pH of the perfusate medium was adjusted
to 7.4 with NaOH. The coverslip, containing the dissociated
hiPSC-derived CMs, was mounted to an RC-25 recording
chamber and continuously perfused with perfusate medium
preheated to 35-36∘C by an SH-27B inline-heater controlled
by a TC-324B unit (all from Warner Instruments Inc.,
Hamden, USA). The perfusion was controlled by a gravity
driven VC38 application system (ALA Scientific Instruments
Inc., NY, USA). Coverslip was perfused for 15 minutes for
Fura-2 AM deesterification before experimental recordings.
Ca2+ handling of spontaneously beating CMs was imaged
with an inverted IX70 microscope using UApo/340 x20 air
objective (Olympus Corporation) and ANDOR iXon 885
CCD camera (Andor Technology, Belfast, Northern Ireland)
synchronized with a Polychrome V light source by a real time
DPS control unit. TILLvisION or Live Acquisition software
(TILL Photonics, Munich, Germany) was used for recording.
Fura-2 AM was excited at 340 nm and 380 nm light and the
emission was recorded for 10–30 seconds at 505 nm.
For Ca2+ imaging analysis, single beating CMs were
selected as regions of interests and background noise,
recorded from a cell-free area in the same coverslip, was
subtracted before further processing. Data is presented as
ratios of 340/380 nm (F340/F380).The spontaneously beating
CMs were divided into five different rhythm categories based
on the abnormalities observed in their Ca2+signals: normal
beating with regular peaks (normal); more than three peaks
which do not return to the baseline (oscillation); signals with
small or middle sized amplitude events in the beginning, in
the end, or in between two Ca2+ spikes (low/middle peaks);
two or three peaks which do not return to the baseline
(double peaks); Ca2+ spikes with prolonged rise or decay time
(plateau abnormality). In the low/middle peaks category, the
small amplitude was at least 10% from the preceding Ca2+
spike amplitude. Full-length, 10–30 seconds long recordings
were analyzed, while most of the analyzed recordings were 12
seconds long. The distribution of CMs in different categories
is presented for each cell lines separately.
2.5.3. ElectrophysiologicalMeasurements: Recording andAnal-
ysis of Action Potentials. The action potentials (APs) were
recorded by conventional patch clamp [19] in perforated
patch configuration using Amphotericin B [20] in final
concentration of 0.24mg/mL [8]. Data acquisition was
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Table 1: TaqMan assays used in qRT-PCR experiments.
Gene Description/alias Function TaqMan assay ID
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 Housekeeping gene Hs00265885 g1
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Housekeeping gene Hs02758991 g1
TNNT2 Troponin T Sarcomeric gene Hs00165960 m1
MYH6 Myosin heavy chain 6 Sarcomeric gene Hs01101425 m1
ACTN2 𝛼-actinin 2 Sarcomeric gene Hs00153809 m1
TPM1 𝛼-tropomyosin Sarcomeric gene Hs00165966 m1
MYBPC3 Myosin-binding protein C Sarcomeric gene Hs00165232 m1
TTN Titin Sarcomeric gene Hs00399225 m1
TNNC1 Troponin C type 1 Sarcomeric gene Hs00896999 g1
MYL9 Myosin, light chain 2/MLC2 Sarcomeric gene Hs00697086 m1
MYL7 Myosin, light chain 7 Sarcomeric gene Hs01085598 g1
NPPA Natriuretic peptide A Hypertrophy marker Hs01081097 m1
NPPB Natriuretic peptide B Hypertrophy marker Hs01057466 g1
HCN4 Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 Potassium channel Hs00975492 m1
KCNQ1 Voltage-gated potassium channel, KQT-like subfamily, member 1 Potassium channel Hs00923522 m1
CACNA1C Voltage-dependent calcium channel, L type, alpha 1C subunit/CaCNA1.2 Calcium channel Hs00167681 m1
SCN5A Voltage-gated sodium channel, V type, alpha subunit Sodium channel Hs00165693 m1
SLC8A1 Solute carrier family 8, member 1/NCX1 Na+/Ca2+ exchanger Hs01062258 m1
PLN Phospholamban/PLB Protein kinase substrate Hs01848144 s1
ATP2A2 ATPase, Ca2+ transporting, cardiac muscle, slow twitch 2/SERCA2a Ca2+-ATPase Hs00544877 m1
CASQ2 Calsequestrin Ca2+ binding protein in SR Hs00154286 m1
ITPR2 Inositol 1,4,5-trisphosphate receptor, type 2/IP3R2 Ca2+ receptor Hs00181916 m1
RYR2 Ryanodine receptor 2 (cardiac) Ryanodine receptor Hs00892883 m1
conducted using Axon Series 200B patch-clamp amplifier
connected to Digidata 1440a AD/DA converter driven by
pCLAMP 10.2 software (all from Molecular devices LLC).
On the day of use, the coverslips containing dissociated
hiPSC-derived CMs were transferred to RC-24N recording
chamber (Warner Instruments Inc.) and mounted on an
inverted Olympus IX71 microscope (Olympus Corporation).
The patch electrodes had tip resistance of 3.0–3.5MΩ and
contained the following intracellular solution (in mM): 132
KMeSO
4
, 20 KCl, 1 MgCl
2
, and 1 CaCl
2
(pH was adjusted to
7.2 with KOH).The extracellular solution contained (in mM)
143 NaCl, 4.8 KCl, 1.8 CaCl
2
, 1.2 MgCl
2
, 5 glucose, and 10
HEPES (pH was adjusted to 7.4 with NaOH). The preheated
extracellular solution was continuously perfused with similar
setup compared to what is presented in Section 2.5.2. Patch
pipettes (Harvard Apparatus Ltd., Holliston, MA, USA)
were freshly prepared using PC-10 micropipette puller and
then flame-polished with MF-830 microforge (both from
Narishige Int., Tokyo, Japan).
APs were recorded in the gap-free mode in the current
clamp from the spontaneously beating hiPSC-derived CMs.
Current-clamp recordings were digitally sampled at 20 kHz
and filtered at 2 kHz using low pass Bessel filter on recording
amplifier. Beats per minute (BPM), AP duration (APD
50
and APD
90
), AP amplitude (APA), and maximum diastolic
potential (MDP) were analyzed from the recorded APs by
using Origin 9.1 (OriginLab Corp., Northampton, USA).
Only ventricular-like waveforms are presented here to avoid
any biasness among different hiPSC lines. The ventricular-
like CMs were characterized by APD
90
/APD
50
< 1.3 and APA
> 90mV.
2.5.4. Real-Time qRT-PCR Analysis. After one week of cul-
ture, dissociated CMs were collected into a lysis solution
buffer of CellsDirect One-Step qRT-PCR Kit (Life Technolo-
gies Ltd.) according to the manufacturer’s instructions. Two
replicate samples were collected and stored at −70∘C until the
DNase I digestion and reverse transcription-specific target
amplification (RT-STA) by using CellsDirect One-Step qRT-
PCR Kit. Real-Time qPCR was performed with Biomark HD
system (Fluidigm Corp., San Francisco, USA) according to
the manufacturer’s instructions. The TaqMan assays (Life
Technologies Ltd.) used in the qRT-PCR are collected in
Table 1. All samples were analyzed in duplicate and the fold
changes were calculated by the 2−ΔΔCT method [21]. EEF1A1
and GAPDH genes were used as endogenous control genes
and UTA.04511.WT cell line was used as a calibrator.
2.5.5. Western Blot. hiPSC-derived CMs were lysed in M-
PER protein extraction reagent (Thermo Scientific, Life
Technologies Ltd.), supplemented with complete protease
inhibitor cocktail (Roche Diagnostics). The protein concen-
tration was quantified with BCA protein assay kit (Thermo
Scientific, Life Technologies Ltd.). 10 𝜇g of protein was run
to 4–15% mini-PROTEAN TGX precast polyacrylamide gel
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(Bio-Rad, Hercules, CA, USA) and transferred to PVDF
membrane (Amersham Hybond-P, GE Healthcare, Little
Chalfont, UK). Membranes were blocked with 5% milk for
1 h at RT and proteins were stained with MYBPC (1 : 1500, sc-
166081, Santa Cruz Biotechnology), cTnT (1 : 2000, ab64623,
Abcam), TPM1 (1 : 200, sc-73225, Santa Cruz Biotechnology),
or 𝛽-actin (1 : 1000, sc-47778, Santa Cruz Biotechnology) pri-
mary antibodies over night at +4∘C. Horseradish peroxidase-
(HRP-) conjugated polyclonal rabbit anti-mouse (DAKO,
P0260) and rabbit anti-goat IgG (Santa Cruz Biotechnology,
sc-2922) were used as secondary antibodies. Stained proteins
were detected by using Clarity ECL substrate (Bio-Rad) and
visualized byMolecular Imager ChemiDOcXRS+ (Bio-Rad).
ImageJ software (National Institutes of Health, USA) was
used to compare the expression of MYBPC, cTnT, and TPM1
with the 𝛽-actin expression from the same cell line.
2.6. Statistical Analysis. For statistical analysis, control cell
lines and cell lines in eachmutationwere combined in groups:
UTA.04602.WT and UTA.04511.WT hiPSC lines in WT-CM
group,UTA.02912.HCMTandUTA.13602.HCMT inHCMT-
CM group, and UTA.07801.HCMM and UTA.06108.HCMM
in HCMM-CM group. Mann-Whitney 𝑈 test with Bonfer-
roni’s correction was used to analyze the differences between
WT-, HCMT-, andHCMM-CMs in cell size analysis, propor-
tion of multinucleated CMs, and Ca2+ imaging experiments
as well as in gene expression analysis. For the statistical
comparison between the three groups, one-way ANOVA
followed by Tukey test was used for the patch-clamp result
analysis. 𝑝 < 0.05 was considered statistically significant. All
error bars are presented as standard error of themean (SEM).
3. Results
3.1. hiPSCs Were Derived from HCM Patients with Different
Backgrounds. Wederived hiPSCs from four patients carrying
a HCM causing mutation either in TPM1 (TPM1-Asp175Asn)
or inMYBPC3 (MYBPC3-Gln1061X). UTA.13602.HCMT and
UTA.02912.HCMTs carry TPM1-Asp175Asn and UTA.07801.
HCMM and UTA.06108.HCMM MYBPC3-Gln1061X muta-
tion. The hiPSC lines and their mutations and abbreviations,
used below, are presented in Table 2. UTA.13602.HCMT (46,
XX) is derived from a 48-year-old female, whose mother
died suddenly at the age of 51. Our patient has had one
collapse at the age of 20 with normal heart structure, but
later slight thickening of septum (16mm) has been observed.
Currently she is not onmedication due to low blood pressure.
UTA.02912.HCMT (46, XY) is derived from a 33-year-old
male whose family member has died suddenly at the age
of 21. The maximal septal thickness of our patient has been
measured to be 26mm on echocardiogram. The patient has
been asymptomatic but is currently on 𝛽-blockermedication.
UTA.07801.HCMM (46, XY) is derived from a 61-year-old
male with no SCDs in the family. On echocardiogram, his
myocardial septum has been observed to be 25mm. He has
atrial fibrillation and he is on 𝛽-blocker medication. Due to
bradycardia and frequent nonsustained ventricular tachycar-
dia episodes, an implantable cardioverter defibrillator (ICD)
Table 2:ThehiPSC lines and theirmutations and abbreviations used
in the study.
Group Cell line Mutation Name inFigure 2(f)
WT UTA.04602.WT — WT1
UTA.04511.WT — WT2
HCMT UTA.02912.HCMT TPM1-Asp175Asn HCMT1
UTA.13602.HCMT TPM1-Asp175Asn HCMT2
HCMM UTA.07801.HCMM MYBPC3-Gln1061X HCMM1
UTA.06108.HCMM MYBPC3-Gln1061X HCMM2
has been implanted. UTA.06108.HCMM (46, XY) is derived
from a 55-year-old male whose father died suddenly at the
age of 36 and uncle at the age of 38. Our patient has been
asymptomatic with maximal septal thickness of 22mm on
echocardiogram. He is not on medication due to low blood
pressure. Control hiPSC lines were derived from healthy
individuals: UTA.04602.WT (46, XX) from a 56-year-old
female andUTA.04511.WT (46, XY) from a 34-year-oldmale.
The pluripotent characteristics of the hiPSC-lines used
were assessed (Figure 1 and Supplementary Figures 1–5).
UTA.04602.WT cell line has been characterized earlier [22].
All the lines formed colonies, which expressed proteins and
genes typical for hPSCs. The virally transferred exogenous
genes were silenced and karyotypes of the hiPSC lines were
normal. The pluripotency of hiPSC lines was proven in
vitro by EB formation or in vivo by teratoma formation.
The presence of TPM1-Asp175Asn and MYBPC3-Gln1061X
mutations in the patient-specific hiPSC lines was confirmed
by custom TaqMan SNP Genotyping Assays (Supplementary
Figure 6).
3.2. Mutation-Specific HCM Phenotypes Were Observed in
hiPSC-Derived Cardiomyocytes. All the cell lines used in the
present study differentiated into cardiomyocytes similarly.
Beating aggregateswere formed 14–20 days after the initiation
of coculturing with END-2 cells and there was no difference
between the lines when the beating areas appeared. After
cardiac differentiation, beating clusters were dissociated into
single cells and cultured for 1, 3, and 6 weeks. The differences
in the cell sizes and Ca2+ handling properties between
two different mutations and control cells were analyzed in
each time point. When comparing different types of CMs,
HCMM-CMswere significantly larger thanHCMT-CMs and
WT-CMs in all three time points (Figures 2(a) and 2(b),
𝑛 = 96–100, 𝑝 < 0.005 in all cases). The enlargement
of HCMT-CMs was detected after three weeks of culture
when they were significantly larger than WT-CMs (𝑝 <
0.005). Generally, the size of the hiPSC-derived CMs in all
groups increased when the cells cultured for three weeks.
Within each group, there were no differences in cell sizes
between three and sixweeks, except withHCMT-CMs, which
seemed to be smaller in size 6-week time point. However,
during 6 weeks of culture, cell types other than CMs had
the tendency to overgrow the CM culture, which might
have affected the cellular enlargement.This phenomenonwas
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Figure 1: Characterization of UTA.13602.HCMT cell line. (a) The hiPSCs formed colonies expressing Nanog, OCT4, SOX2, TRA-1-60, and
TRA-1-81. Scale bars: 200 𝜇m. (b)The virally transferred Sendai exogenes, exo-OCT4 (483 bp), exo-KLF4 (410 bp), exo-SOX2 (451 bp), and exo-
c-MYC (532 bp), were silenced in the hiPSCs. + indicates positive controls, for which RNAwas extracted from cells 1 week after transduction.
hiPSCs expressed endogenous Nanog (287 bp), OCT4 (144 bp), REX1 (306 bp), SOX2 (151 bp), and c-MYC (328 bp). GAPDH (302 bp) was
used as a housekeeping control. (c) The hiPSC line was karyotypically normal, 46 XX. (d) The pluripotency of hiPSCs was confirmed by in
vivo teratoma assay, in which hiPSCs formed all three germ layers (mesoderm, endoderm, and ectoderm).
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Figure 2: The cell size and Ca2+ handling of hiPSC-derived CMs after 1-, 3-, and 6-week culture as single cells. (a) Representative images of
WT-CMs (WT), HCMT-CMs (HCMT), and HCMM-CMs (HCMM) stained with antibodies for cTnT (red) and MYBPC (green) proteins.
Scale bars are 100𝜇m. (b) The size of the HCMM-CMs was significantly larger in all three time points when compared to WT- and HCMT-
CMs ($$𝑝 < 0.005 when compared to WT-CMs or HCMT-CMs in the 1-week time point, ∗∗𝑝 < 0.005 when compared to WT-CMs or
HCMT-CMs in 3-week time point, and ##𝑝 < 0.005 when compared to WT-CMs or HCMT-CMs in 6-week time point). HCMT-CMs
were significantly larger than WT-CMs in 3-week time point (&&𝑝 < 0.005 when compared to WT-CMs. 𝑛 = 100, except in HCMT 6w
𝑛 = 96.) (c) The proportion of the multinucleated CMs was significantly higher in HCMT-CMs than in WT-CMs and HCMM-CMs when
both cell lines and all time points were combined for each group (in statistical analysis 𝑛 = 6, ∗𝑝 < 0.05). The averages of multinucleated
CMs were determined from the same cells, whose sizes and 𝑛 numbers are presented in (b). (d) Significantly more CMs with Ca2+ handling
abnormalities were observed in HCMT-CMs than in WT-CMs and HCMM-CMs when both cell lines and all time points were combined
for each group (in statistical analysis 𝑛 = 6, ∗𝑝 < 0.05). The proportions of CMs with abnormalities in their Ca2+ handling were determined
from the same Ca2+ imaging results presented in (f). The total 𝑛 numbers of the analyzed CMs are presented in (f). (e) Representative
images of Ca2+ rhythm categories. (f) Distributions of hiPSC-derived CMs in different Ca2+ rhythm categories (e) in each time point. WT1 =
UTA.04602.WT, WT2 = UTA.04511.WT, HCMT1 = UTA.02912.HCMT, HCMT2 = UTA.13602.HCMT, HCMM1 = UTA.07801.HCMM, and
HCMM2 = UTA.06108.HCMM.
observed especially with UTA.13602.HCMT cell line (data
not shown). When all time points in each group (WT-CM,
HCMT-CM, and HCMM-CM) were combined, the number
of multinucleated CMs was significantly higher in HCMT-
CMs than inWT-CMs and HCMM-CMs (𝑛 = 6 in statistical
analysis, 𝑝 < 0.05, Figure 2(c)).
TheCa2+handling properties of hiPSC-derived CMswere
studied byCa2+ imaging.HCMT-CMs had significantlymore
abnormalities than WT-CMs and HCMM-CMs, when all
time points in each group were combined (Figure 2(d), 𝑛 =
6 in statistical analysis, 𝑝 < 0.05). Spontaneously beating
CMs were divided into five different rhythm categories
(normal, oscillation, low/middle peaks, double peaks, and
plateau abnormality) based on the abnormalities observed in
their Ca2+ signals (Figures 2(e) and 2(f)). HCMT-CMs had
significantly higher number of double peaks than HCMM-
CMs (𝑝 < 0.05, 𝑛 = 6 in statistical analysis) when both cell
lines and all time points were combined for each group.
3.3. Action Potential Characteristics of WT and HCM hiPSC-
Derived Cardiomyocytes. The spontaneous action potentials
were recorded from the beating hiPSC-derived CMs to
establish the electrophysiological baselines. Most of the cells
(>80%) were ventricular-like CMs in all the hiPSC lines
studied. For this reason, only ventricular-like waveforms
are presented here. We first analyzed the percentage of
the arrhythmias in each cell line (Figures 3(a)–3(f)) and
found similar percentage in both cell lines within the
groups (UTA.04602.WT (13%) versus UTA.04511.WT (15%),
UTA.02912.HCMT (42%) versus UTA.13602.HCMT (47%),
and UTA.07801.HCMM (50%) versus UTA.06108.HCMM
(50%)). Based on the percentage of the arrhythmias, we com-
bined hiPSC-derived CMs into groups (WT-CM, HCMT-
CM, and HCMM-CM) for further analysis.
Both HCMT-CMs and HCMM-CMs had more
arrhythmic events including delayed after depolarizations
(DADs) and early after depolarizations (EADs) when
compared to the WT-CMs (WT-CM (14%), HCMT-
CM (45%), and HCMM-CM (50%)). We quantified the
occurrence of DADs in hiPSC-derived CMs as a rate
(DADs/min) calculated as total number of DADs/total
number of APs. We found that the DAD rate in HCMM-
CMs was significantly higher than in WT-CMs (Figure 3(g),
𝑝 < 0.005).
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Figure 3: Arrhythmogenic events (DADs and EADs) were observed in HCM-CMs. (a)–(e) Representative recordings of control hiPSC-
derived CMs (WT) and hiPSC-derived CMs carrying TPM1-Asp175Asn (HCMT) orMYBPC3-Gln1061X (HCMM)mutations. Typical DADs
(arrows) are presented in (b) and (c) and EADs (arrows) in (d) and (e) for HCMT-CMs and HCMM-CMs, respectively. Scale bars represent
40mv and 5 seconds, respectively. Scale bars in (a) are representative for (b) and (c), and scale bars in (d) are representative for (e). (f)
Distribution of CMs exhibiting arrhythmogenic events in each cell line. (g) DAD rate was significantly higher in HCMM-CMs than in WT-
CMs (∗∗𝑝 < 0.005).
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Table 3: AP properties of ventricular-like CMs derived from control hiPSC lines (WT) and from hiPSC lines carrying TPM1-Asp175Asn
(HCMT) orMYBPC3-Gln1061X (HCMM) mutations. In the results, the data of each group is comprised from two separate cell lines.
Group 𝑛 Beating rate APD50 APD90 APA MDP
(BPM) (ms) (ms) (mV) (mV)
WT 43 58.1 ± 2.3 277.3 ± 13.0 323.6 ± 13.9 119.5 ± 1.1 −76.8 ± 0.8
HCMT 71 48.4 ± 1.5∗∗ 372.3 ± 13.2∗∗ 433.1 ± 14.0∗∗ 121.2 ± 1.1 −75.8 ± 0.7
HCMM 54 47.1 ± 1.8∗∗ 319.5 ± 13.7$ 377.6 ± 15.0∗,$ 124.3 ± 1.4∗ −77.9 ± 0.8
∗HCMT or HCMM versus WT.
$HCMM versus HCMT.
$ or ∗𝑝 < 0.05 and ∗∗𝑝 < 0.005.
The average APD at 50% repolarization (APD
50
) and
90% repolarization (APD
90
) of HCMT-CMswas significantly
longer than those of the WT-CMs (APD
50
(𝑝 < 0.005) and
APD
90
(𝑝 < 0.005)) and HCMM-CMs (APD
50
(𝑝 < 0.05)
and APD
90
(𝑝 < 0.05)) (Table 3). APD
90
of HCMM-CMs
was significantly longer than that of the WT-CMs (𝑝 < 0.05)
(Table 3). Furthermore, the beating rates of both HCMT-
CMs and HCMM-CMs were significantly lower than inWT-
CMs (WT-CM versus HCMT-CM (𝑝 < 0.005) and WT-CM
versus HCMM-CM (𝑝 < 0.005)). In addition, the APA of
HCMM-CMs was significantly higher than in the WT-CMs
(𝑝 < 0.05). However, no significant differences were found
for the MDP between any groups (Table 3).
3.4. Differences in the Gene Expression Profiles of hiPSC-
Derived Cardiomyocytes. Dissociated hiPSC-derived CMs
were cultured for one week before qRT-PCR analysis was
performed.The results are presented in Figure 4.The expres-
sion of sarcomeric genes MYBPC3, TNNT2, ACTN2, TTN,
MYL7, and MYL9 was significantly higher in both HCMT-
CMs andHCMM-CMs than in theWT-CMs (𝑝 < 0.005 in all
cases). The expression of TPM1 and TNNC1 was significantly
increased only in the HCMM-CMs when compared to WT-
CMs (𝑝 < 0.005 in both cases). On the other hand, the
expression of MYH6 was on the same level in all hiPSC-
derived CMs. Moreover, the expression of some sarcomeric
genes (TNNT2, ACTN2, TNNC1, TTN, MYL7, and MYL9)
was significantly higher in the HCMM-CMs than in the
HCMT-CMs (𝑝 < 0.005 in other than TNNT2 and MYL9
𝑝 < 0.05). The expression of natriuretic peptide A (NPPA)
was similar in all hiPSC-derived CMs while the expression of
natriuretic peptide B (NPPB) was increased in HCMT-CMs
and HCMM-CMs when compared to WT-CMs (𝑝 < 0.005
in both cases). Nodal marker HCN4 was also significantly
increased in both HCM-CMs when compared to WT-CMs
(𝑝 < 0.05 for HCMT-CMs versus WT-CMs and 𝑝 < 0.005
for HCMM-CMs versus WT-CMs). Further, the highest
expression of potassium channelKCNQ1 and sodium channel
SCN5A as well as sodium calcium exchanger SLC8A1 was
observed in HCMM-CMs (𝑝 < 0.005 when compared to
WT-CMs in all cases).
We found differences also in the expression of genes
related to the Ca2+ handling. The expression of CACNA1C
and PLN was increased in both HCMT-CMs (𝑝 < 0.05
for CACNA1C and 𝑝 < 0.005 for PLN) and HCMM-CMs
(𝑝 < 0.005 in both cases) when compared to WT-CMs
while the expression of ATP2A2 and ITPR2 was on the same
level in all hiPSC-derived CMs. However, the expression of
CASQ2 and RYR2 was significantly higher in HCMT-CMs
and HCMM-CMs when compared to WT-CMs (𝑝 < 0.005
in all cases). Moreover, the expression of RYR2 was almost
six times higher in the HCMM-CMs than in the WT-CMs
(𝑝 < 0.005) and around three times higher than in HCMT-
CMs (𝑝 < 0.005).
3.5. Truncated MYBPC Protein Was Not Detected in hiPSC-
Derived Cardiomyocytes Carrying MYBPC3-Gln1061X Muta-
tion. Both wild type and the mutant TPM1 mRNA were
present in HCM-CMs carrying the TPM1-Asp175Asn muta-
tion while hiPSC-derived control CMs expressed only wild
typemRNA.However, in hiPSC-CMs carrying theMYBPC3-
Gln1061X mutation the mutant mRNA was not clearly
detected (Supplementary Figure 7). At a protein level all
hiPSC-derived CMs expressed MYBPC, cTnT, and TPM1
(Figures 5(a) and 5(b)). The truncated MYBPC protein (pre-
dicted size: 116 kDa) was not detected in HCMM-CMs with
western blot analysis (Figure 5(b)). However, the expression
level of total MYBPC was slightly reduced in HCMM-CMs
when compared to WT-CMs (Figure 5(c)). In addition, the
expression of cTnT and TPM1 was elevated in both HCM-
CMs (Figure 5(c)).
4. Discussion
Here we have analyzed characteristics of hiPSC-derived
HCM-CMs carrying either TPM1-Asp175Asn or MYBPC3-
Gln1061X gene mutation. The size of theMYBPC3-Gln1061X
CMs was significantly larger than that of TPM1-Asp175Asn
CMs, while the CMs carrying the latter mutation had
significantly more abnormal Ca2+ transients. Additionally,
CMs with TPM1-Asp175Asnmutation had significantly more
prolonged action potentials. However, both types of HCM-
CMs had increased amount of arrhythmogenic events (DADs
and EADs) in electrophysiological recordings when com-
pared to control CMs. In addition to morphological and
functional differences, also gene expression profiles were
different between CMs carrying either TPM1-Asp175Asn or
MYBPC3-Gln1061X gene mutation.
GeneticHCM is primarily due tomutations in sarcomeric
genes, while changes at the cellular level include disturbed
Ca2+metabolism and decreased contraction force generation
in addition to enlarged cell size [23]. To our knowledge,
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Figure 4: Gene expression profiles in control hiPSC-derived CMs (WT) and in hiPSC-derived CMs carrying TPM1-Asp175Asn (HCMT)
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total of three reports studying the characteristics as well as
the pathophysiological mechanisms of the HCM by using
the patient-specific hiPSCs have been published [12–14]. In
two of these publications, the mutation is located in the
MYH7 (MYH7-R663H or MYH7-R442G) [12, 13], whereas,
in the most recent publication, the hiPSCs were derived from
three HCM patients, from whom one carried the MYBPC3-
999-1004del2, while the other mutations were unknown [14].
In addition to these three publications, hiPSC-derived CMs
carrying MYBPC3 mutations have been used in one study
where the effects of serum on the phenotype of neonatal
rat CMs as well as hPSC-derived CMs have been explored
[24]. hiPSC-derived CMs carrying MYBPC3 mutation were
used only when studying the effects of serum on the cellular
enlargement [24]. In this current study, we obtained hiPSCs
from HCM patients carrying either the MYBPC3-Gln1061X
or TPM1-Asp175Asn mutation. We believe that this is the
first report where hiPSC-derived CMs carrying different gene
mutations have been compared in the same studywith similar
experimental settings.
OurHCM-CMs demonstrated cellular enlargement simi-
larly to previous HCM studies with hiPSCs [12–14]. However,
we observed a significant difference in the cellular enlarge-
ment between the two HCM mutations. CMs carrying the
MYBPC3-Gln1061X mutation presented more pronounced
and earlier cellular enlargement than CMs carrying the
TPM1-Asp175Asn mutation. In a previous study, serum has
been shown to mask hypertrophic phenotype of the CMs
with mutations in the MYBPC3 [24]. The CMs from the
HCM patients were larger in serum-free conditions without
any external stimuli, while the serum seemed to increase
the cellular enlargement in WT-CMs but not in CMs with
HCMmutations [24].We used 20% serum in our CM culture
medium that did not seem to mask the cellular enlargement
with our CMs. Already after one week of culture, CMs car-
rying MYBPC3-Gln1061X mutation were significantly larger
than theWT-CMs.The enlargement of CMs carrying TPM1-
Asp175Asn mutation was detectable only after three weeks
of culture. In the previous clinical studies, as well as in the
patient data analyzed in this current study, the hypertrophy
has been in the same range in patients carrying either of these
two mutations [2]. Therefore, these differences in CM size
between the two mutations do not correlate with the extent
of clinical hypertrophy.
The higher Ca2+ sensitivity, observed in animal models
and myectomy samples, has been suggested to be a common
feature for allHCMmutations [25, 26]. In the previous studies
with hiPSC-derived CMs, irregularities in Ca2+ transients
have been observed in the MYH7-R663H and the MYH7-
R442G mutations [12, 13]. The higher Ca2+ sensitivity has
been related to lower phosphorylation levels of the MYBPC
and the Troponin I proteins and the difference could at
least partly be explained by hypophosphorylation of the
sarcomeric proteins compared to the actual mutations [26].
In our study, the amount of abnormalities in Ca2+transients
was significantly increased only in the hiPSC-derived CMs
with the TPM1-Asp175Asn mutation. Indeed, the amount
of irregularities in Ca2+ handling properties was similar in
the MYBPC3-Gln1061X compared to that in the WT-CMs.
The phosphorylation of the proteins was not analyzed in
this current study. However, we analyzed the expression of
genes related to Ca2+ handling and they were at the highest
level in hiPSC-derived CMs carrying theMYBPC3-Gln1061X
mutation. This might be at least partly due to the larger cell
size of these CMs. Han and coworkers found decreased level
of RYR2 expression in HCM-CMs carrying MYH7-R442G
mutation [13], while in our study the expression of RYR2 was
significantly higher in both mutations and almost six times
higher in the hiPSC-derived CMs carrying the MYBPC3-
Gln1061Xmutation than in theWT-CMs.These observations
suggest that abnormal Ca2+ transients inHCM-CMs carrying
different mutations may be caused by distinct mechanisms.
One of the fundamental features of the HCM is its
association with ventricular arrhythmias responsible for
severe cardiac malfunctions including sudden cardiac death
[27, 28]. We found increased amount of arrhythmogenic
events (DADs and EADs) in both HCM-CMs. Furthermore,
decreased beating rate was observed in both types of HCM-
CMs, which could be due to higher occurrence of DADs
between the two consecutive APs. In addition, the APD
90
of hiPSC-derived CMs carrying either TPM1-Asp175Asn or
MYBPC3-Gln1061X mutation was longer than in WT-CMs,
which is in line with previous findings with different muta-
tions [12, 13, 29]. The mechanism of arrhythmias in HCM
is not yet fully understood; however, imbalances in Ca2+
homeostasis are considered as a main cause of arrhythmias
shown in the previous studies [12, 13]. Clinically, patients
carrying TPM1-Asp175Asn mutation have been reported to
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Figure 5: Cardiac-specific protein expression in hiPSC-derived CMs. (a) Representative images of hiPSC-derived CMs carrying TPM1-
Asp175Asnmutation (HCMT) orMYBPC3-Gln1061Xmutation (HCMM) and hiPSC-derived control CMs (WT) stained with cTnT, MYBPC,
and TPM1. These images are not to quantify the protein expression but to demonstrate the presence of cTnT, MYBPC, and TPM1 proteins in
the hiPSC-derived CMs. (b) hiPSC-derived CMs from all cell lines expressed MYBPC, cTnT, and TPM1 proteins.The truncated MYBPC was
not detected in HCMM cells (size of the wild type protein 141 kDa and the predicted size of the truncated protein 117 kDa). (c)The expression
of MYBPC, cTnT, and TPM1 inWT-CMs, HCMT-CMs, and HCMM-CMs normalized to the expression of 𝛽-actin. Protein expressions were
quantified from western blots using ImageJ software. Quantitation data show the averages of MYBPC/𝛽-actin, cTnT/𝛽-actin, and TPM1/𝛽-
actin relations from hiPSC-derived CMs from two different hiPSC lines in each group. Because of the lack of replicates, statistical analysis
was not performed.
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be more prone to arrhythmias than those carryingMYBPC3-
Gln1061X mutation [30]. Our data with hiPSC-derived CMs
support this finding by demonstrating more abnormal Ca2+
transients and longer APD
90
in TPM1-Asp175Asn CMs than
in HCM-CMs carrying theMYBPC3-Gln1061X mutation.
Likemost of theHCMmutations located in theMYBPC3,
also MYBPC3-Gln1061X is a nonsense mutation that leads
to premature stop-codon [31]. Nonsense mutations are sug-
gested to act through haploinsufficiency inwhich themutated
protein is either degraded or not produced at all. The
truncated form of MYBPC has not been found in human
cardiac samples while the total expression level of MYBPC
has been reported to vary from being decreased to even
increased [32–36]. Interestingly, when studying myectomy
samples from HCM hearts with MYBPC3 mutation, Helms
et al. observed that the total amount ofMYBPC3mRNA was
increased, while the total amount of MYBPC protein was
on the same level compared to that in the control hearts.
They hypothesized that the upregulation of the MYBPC3
compensates the degraded truncated MYBPC protein [35].
We could not detect mutant allele on mRNA expression
level or truncated MYBPC protein in hiPSC-derived CMs
carrying theMYBPC3-Gln1061Xmutation. Similar absence of
truncated protein has been reported earlier with a different
MYBPC mutation in hiPSC-derived CMs [14]. These data
suggest that the mutant mRNAmight be degraded. However,
further research is still needed to confirm the results and to
discover the actual degradation mechanism.
The two HCM mutations analyzed in this study are the
most frequent mutations in Finland accounting for about
18% of all Finnish HCM patients [3]. In our study, we
found differences in the morphological and biochemical
properties, as well as in Ca2+ cycling and electrophysio-
logical properties between the CMs carrying either TPM1-
Asp175Asn or MYBPC3-Gln1061X mutation. However, we
have not analyzed the possible effects of other genemutations
and epigenetic factors on the phenotype differences observed
in our study. Additionally, we used only two hiPSC lines from
two different patients in each mutation in our experiments.
In the future, we need to extend our studies including further
patients and studying the effects of additional genemutations
and epigenetic factors. The immature nature of hiPSC-
derived CMs is a general limitation when using these cells in
disease modeling. Further development in the differentiation
and maturation protocols will increase the reliability of
studies conductedwith hiPSC-derivedCMs. Finally, the exact
pathophysiology in abnormal Ca2+ transients or electrical
abnormalities is not known and further research with com-
bined patch clamp and Ca2+ imaging is required in the future
to reveal the significance of the cellular findings for clinical
phenotypes as well as for treatment options.
5. Conclusions
In conclusion, both HCM hiPSC-derived CMs either car-
rying the TPM1-Asp175Asn or MYBPC3-Gln1061X mutation
exhibited pathological changes related to HCM. However,
significant differences between the two mutations were
observed. The hiPSC-derived cell models, established in this
study, can be exploited to study further the pathophysio-
logical mechanisms of HCM as well as to screen drugs and
potentially optimize treatments in mutation-specific way.
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